Hiroteru Kamimura
Overview
Explore the profile of Hiroteru Kamimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kanda T, Sasaki-Tanaka R, Kimura N, Abe H, Yoshida T, Hayashi K, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076514
Patients with chronic cholestatic liver diseases often experience itch and struggle with this symptom. We discuss the mechanism of itch in patients with chronic cholestatic liver diseases, such as primary...
2.
Toriu N, Sato Y, Kamimura H, Yoshikawa T, Tanaka M, Yamamoto S, et al.
PLoS One
. 2025 Feb;
20(2):e0311193.
PMID: 40014629
Tertiary lymphoid tissues (TLTs) are ectopic lymphoid structures induced by multiple stimuli, including infection and tissue injuries; however, their clinical relevance in disease progression has remained unclear. We demonstrated previously...
3.
Ishikawa N, Watanabe Y, Maeda Y, Yoshida T, Kimura N, Abe H, et al.
Regen Ther
. 2025 Feb;
28:509-516.
PMID: 39991509
Introduction: Cirrhosis is a disease with poor prognosis that requires the development of a novel therapeutic approach alternative to liver transplantation. In this study, we focused on the placenta and...
4.
Yakubo S, Abe H, Li Y, Kudo M, Kimura A, Wakabayashi T, et al.
Diseases
. 2024 Dec;
12(12.
PMID: 39727647
Metabolic dysfunction-associated steatotic liver disease (MASLD) causes cellular senescence due to oxidative stress, endoplasmic reticulum stress, and ectopic fat deposition in the liver. Recently, dasatinib, an antitumor agent, and quercetin,...
5.
Maeda Y, Watanabe Y, Ishikawa N, Yoshida T, Kimura N, Abe H, et al.
Regen Ther
. 2024 Nov;
26:1048-1057.
PMID: 39569343
Introduction: Cirrhosis remains a significant clinical challenge due to its poor prognosis and limited treatment options, creating a high unmet medical need for the development of novel therapies. In this...
6.
Yamazaki S, Watanabe Y, Takahashi K, Tominaga K, Ikarashi S, Yokoo T, et al.
Intern Med
. 2024 Oct;
PMID: 39401910
Among causes of liver failure, liver failure due to lymphocytic infiltration is rare. Unlike typical liver failure, some cases present with severe lactic acidosis and a poor prognosis. We herein...
7.
Tanaka A, Tsuji K, Komiyama Y, Tsuruya K, Kakisaka K, Tsutsui A, et al.
Hepatol Res
. 2024 Apr;
54(6):503-512.
PMID: 38642343
Aim: The diagnosis of drug-induced liver injury (DILI) is challenging. We modified the revised electronic version of the Roussel Uclaf Causality Assessment Method (RUCAM) for the diagnosis of DILI (RECAM),...
8.
Nagayama I, Kamimura K, Owaki T, Ko M, Nagoya T, Tanaka Y, et al.
Hepatol Int
. 2024 Mar;
18(3):1067-1069.
PMID: 38451408
No abstract available.
9.
Nagayama I, Kamimura K, Owaki T, Ko M, Nagoya T, Tanaka Y, et al.
Hepatol Int
. 2023 Oct;
18(1):155-167.
PMID: 37864724
Background: Insulin-like growth factor-1 (IGF-1) is involved in the pathology of non-alcoholic fatty liver disease (NAFLD) and ameliorates fatty infiltration in the liver. It is activated by growth hormone (GH);...
10.
Kimura N, Takahashi K, Setsu T, Horibata Y, Kaneko Y, Miyazaki H, et al.
Hepatol Res
. 2023 Sep;
54(1):67-77.
PMID: 37691006
Aims: Ursodeoxycholic acid is the first-line treatment for primary biliary cholangitis, and treatment response is one of the factors predicting the outcome. To prescribe alternative therapies, clinicians might need additional...